NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
Clinical Trials
17 trialsNCT07232602 2026-03-16
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07287995 2026-03-16
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06862219 2026-03-06
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT06434350 2026-03-02
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06809140 2026-02-23
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05239624 2026-02-19
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07221942 2026-02-19
IMPROEV
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05868265 2026-02-17
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06724159 2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT05775471 2026-02-05
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT06553885 2026-01-29
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07110038 2026-01-12
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05656235 2026-01-08
Renal Retention in High Grade Upper Tract Urothelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting